Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure

Cytokine

Volumn 80, Issue , 2016, Pages 7-12

  Ptaszynska Kopczynska, Katarzyna ^a   Marcinkiewicz Siemion, Marta ^a   Lisowska, Anna ^a   Waszkiewicz, Ewa ^a   Witkowski, Marcin ^a   Jasiewicz, Malgorzata ^a   Miklasz, Paula ^a   Jakim, Piotr ^b   Galar, Bogdan ^b   Musial, Wlodzimierz Jerzy ^a   Kaminski, Karol Adam ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Division of Cardiology   (Poland)

Author keywords

Chronic heart failure; Inflammation; Soluble receptor CD163 (sCD163); Soluble tumor necrosis factor like weak inducer of apoptosis (sTWEAK)

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CD163 ANTIGEN; SOLUBLE RECEPTOR CD163; SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ACETYLSALICYLIC ACID LYSINATE; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; LYSINE; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 12;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; EXERCISE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; COMPLICATION; DOWN REGULATION; INFLAMMATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ASPIRIN; CASE-CONTROL STUDIES; CYTOKINE TWEAK; DOWN-REGULATION; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; LYSINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, CELL SURFACE; RISK FACTORS; TUMOR NECROSIS FACTORS;

EID: 84977647824     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.02.005     Document Type: Article

References (30)

1. [1] Braunwald, E., Bristow, M.R., Congestive heart failure: fifty years of progress. Circulation, 102(20), 2000 IV 14–23.
2. [2] Satoh, M., Minami, Y., Takahashi, Y., Nakamura, M., Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. Curr. Heart Fail. Rep. 5 (2008), 69–74.
3. [3] Seta, Y., Shan, K., Bozkurt, B., Oral, H., Mann, D.L., Basic mechanisms in heart failure: the cytokine hypothesis. J. Card. Fail. 2 (1996), 243–249.
4. [4] Ferrari, R., Bachetti, T., Confortini, R., Opasich, C., Febo, O., Corti, A., et al. Tumour necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92 (1995), 1479–1486.
5. [5] Burkly, L.C., Michaelson, J.S., Hahm, K., Jakubowski, A., Zheng, T.S., TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 40 (2007), 1–16.
6. [6] Novoyatleva, T., Diehl, F., van Amerongen, M.J., Patra, C., Ferrazzi, F., Bellazzi, R., et al. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc. Res. 85 (2010), 681–690.
7. [7] Jain, M., Jakubowski, A., Cui, L., Shi, J., Su, L., Bauer, M., et al. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 119 (2009), 2058–2068.
8. [8] Chorianopoulos, E., Jarr, K., Steen, H., Giannitsis, E., Frey, N., Katus, H.A., Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 211:1 (2010), 322–326.
9. [9] Chorianopoulos, E., Rosenberg, M., Zugck, C., Wolf, J., Katus, H.A., Frey, N., Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur. J. Heart Fail. 11:11 (2009), 1050–1056.
10. [10] Richtera, B., Rychlia, K., Hohensinnera, P.J., Bergera, R., Mörtla, D., Neuholda, S., et al. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 213 (2010), 545–548.
11. [11] Van Gorp, H., Delputte, P.L., Nauwynck, H.J., Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol. Immunol. 47 (2010), 1650–1660.
12. [12] Bover, L.C., Cardó-Vila, M., Kuniyasu, A., Sun, J., Rangel, R., Takeya, M., et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J. Immunol. 178 (2007), 8183–8194.
13. [13] Landis, R.C., Philippidis, P., Domin, J., Boyle, J.J., Haskard, D.O., Haptoglobin genotype-dependent anti-inflammatory signaling in CD163(+) macrophages. Int. J. Inflam., 2013, 2013, 980327.
14. [14] Sulahian, T.H., Hogger, P., Wahner, A.E., Wardwell, K., Goulding, N.J., Sorg, C., et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 12 (2000), 1312–1321.
15. [15] Schaer, D.J., Boretti, F.S., Schoedon, G., Schaffner, A., Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids. Br. J. Haematol. 119 (2002), 239–243.
16. [16] Buechler, C., Ritter, M., Orsó, E., Langmann, T., Klucken, J., Schmitz, G., Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J. Leukoc. Biol. 67:1 (2000), 97–103.
17. [17] Dige, A., Støy, S., Thomsen, K.L., Hvas, C.L., Agnholt, J., Dahlerup, J.F., et al. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease. Scand. J. Immunol. 80:6 (2014), 417–423.
18. [18] Schenk, M., Fabri, M., Krutzik, S.R., Lee, D.J., Vu, D.M., Sieling, P.A., et al. Interleukin-1β triggers the differentiation of macrophages with enhanced capacity to present mycobacterial antigen to T cells. Immunology 141:2 (2014), 174–180.
19. [19] Evans, B.J., Haskard, D.O., Sempowksi, G., Landis, R.C., Evolution of the macrophage CD163 phenotype and cytokine profiles in a human model of resolving inflammation. Int. J. Inflam., 2013, 2013, 780502.
20. [20] Aristoteli, L.P., Møller, H.J., Bailey, B., Moestrup, S.K., Kritharides, L., The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 184 (2006), 342–347.
21. [21] Urbonavicienea, G., Martin-Venturab, J.L., Lindholta, J.S., Urbonaviciusa, S., Morenob, J.A., Egidob, J., et al. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis 219 (2011), 892–899.
22. [22] Blanco-Colio, L.M., Martín-Ventura, J.L., Muñóz-García, B., Orbe, J., Páramo, J.A., Michel, J.B., et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27 (2007), 916–922.
23. [23] Kralisch, S., Ziegelmeier, M., Bachmann, A., Seeger, J., Lössner, U., Blüher, M., et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 199 (2008), 440–444.
24. [24] Bonda, T., Kaminski, K.A., Kozuch, M., Kozieradzka, A., Wojtkowska, I., Dobrzycki, S., et al. Circadian variations of interleukin 6 in coronary circulations of patients with myocardial infarction. Cytokine 50:2 (2010), 204–209.
25. [25] Simón-Muela, I., Llauradó, G., Chacón, M.R., Olona, M., Näf, S., Maymó-Masip, E., et al. Reduced circulating levels of TWEAK are associated with gestational diabetes mellitus. Eur. J. Clin. Invest. 45:1 (2015), 27–35.
26. [26] Jasiewicz, M., Kowal, K., Kowal-Bielecka, O., Knapp, M., Skiepko, R., Bodzenta-Lukaszyk, A., et al. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension. Cytokine 66:1 (2014), 40–45.
27. [27] Batista, M.L. Jr., Santos, R.V., Cunha, L.M., Mattos, K., Oliveira, E.M., Seelaender, M.C., et al. Changes in the pro-inflammatory cytokine production and peritoneal macrophage function in rats with chronic heart failure. Cytokine 34:5–6 (2006), 284–290.
28. [28] Møller, H.J., Peterslund, N.A., Graversen, J.H., Moestrup, S.K., Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99 (2002), 378–380.
29. [29] Kowal, K., Silver, R., Sławinska, E., Bielecki, M., Chyczewski, L., Kowal-Bielecka, O., CD163 and its role in inflammation. Folia Histochem. Cytobiol. 9 (2011), 365–374.
30. [30] Valdivielso, J.M., Coll, B., Martín-Ventura, J.L., Moreno, J.A., Egido, J., Fernández, E., Blanco-Colio, L.M., Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J. Nephrol. 26:6 (2013), 1105–1113.